Abstract P2-10-18: A study to evaluate the safety and efficacy of vosilasarm (EP0062), an oral SARM, as monotherapy and in combination with standard of care regimens in patients with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer
Joyce O’Shaughnessy(Baylor University Medical Center), Hyo S. Han(Moffitt Cancer Center), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Valentina Boni, Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Susan Brook, Anne Armstrong(The Christie NHS Foundation Trust), Geoff Fisher, Patricia LoRusso(Yale Cancer Center), Meritxell Bellet Ezquerra, Noelia Martínez-Jáñez(Instituto Cajal), Carlo Palmieri(University of Liverpool), Elisa Fontana(Sarah Cannon Research Institute), Sital Patel, Erika Hamilton(Sarah Cannon)
Cited by 0
Related Papers
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|960